×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
KURA – kura oncology, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
KURA
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/21
11:34 am
kura
Kura Oncology, Inc. (NASDAQ: KURA) had its "buy" rating re-affirmed by analysts at TD Cowen.
Low
Report
Kura Oncology, Inc. (NASDAQ: KURA) had its "buy" rating re-affirmed by analysts at TD Cowen.
11/21
10:45 am
kura
Kura Oncology Slams The Door On Its Takeover Narrative, And Shares Collapse 26% [Yahoo! Finance]
Low
Report
Kura Oncology Slams The Door On Its Takeover Narrative, And Shares Collapse 26% [Yahoo! Finance]
11/21
09:45 am
kura
Kura Oncology, Inc. (NASDAQ: KURA) had its price target lowered by analysts at Jefferies Financial Group Inc. from $32.00 to $28.00. They now have a "buy" rating on the stock.
Low
Report
Kura Oncology, Inc. (NASDAQ: KURA) had its price target lowered by analysts at Jefferies Financial Group Inc. from $32.00 to $28.00. They now have a "buy" rating on the stock.
11/21
09:00 am
kura
Kura Oncology, Inc. (NASDAQ: KURA) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
High
Report
Kura Oncology, Inc. (NASDAQ: KURA) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
11/21
08:05 am
kura
Kura Oncology, Inc. (NASDAQ: KURA) had its price target raised by analysts at HC Wainwright from $32.00 to $37.00. They now have a "buy" rating on the stock.
High
Report
Kura Oncology, Inc. (NASDAQ: KURA) had its price target raised by analysts at HC Wainwright from $32.00 to $37.00. They now have a "buy" rating on the stock.
11/20
05:02 pm
kura
Kura Oncology and Kyowa Kirin Announce Global Strategic Collaboration to Develop and Commercialize Ziftomenib in Acute Leukemias [Yahoo! Finance]
High
Report
Kura Oncology and Kyowa Kirin Announce Global Strategic Collaboration to Develop and Commercialize Ziftomenib in Acute Leukemias [Yahoo! Finance]
11/20
05:00 pm
kura
Kura Oncology and Kyowa Kirin Announce Global Strategic Collaboration to Develop and Commercialize Ziftomenib in Acute Leukemias
High
Report
Kura Oncology and Kyowa Kirin Announce Global Strategic Collaboration to Develop and Commercialize Ziftomenib in Acute Leukemias
11/20
05:00 pm
kura
Kura Oncology and Kyowa Kirin Announce Global Strategic Collaboration to Develop and Commercialize Ziftomenib in Acute Leukemias
High
Report
Kura Oncology and Kyowa Kirin Announce Global Strategic Collaboration to Develop and Commercialize Ziftomenib in Acute Leukemias
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
11/19
12:46 pm
Reiterates
Market Outperform
Market Outperform
JMP Securities
Medium
Report
-3.3%
11/19
12:46 pm
Reiterates
Market Outperform
Market Outperform
JMP Securities
Medium
Report
-3.3%
11/19
12:39 pm
Reiterates
Market Outperform
Market Outperform
JMP Securities
Medium
Report
-3.5%
11/19
12:39 pm
Reiterates
Market Outperform
Market Outperform
JMP Securities
Medium
Report
-3.5%
Date
Time
Symbol
Headline
Impact
11/20
05:21 pm
kura
Form 8-K Kura Oncology, Inc. For: Nov 20
High
Report
Form 8-K Kura Oncology, Inc. For: Nov 20
11/19
04:05 pm
kura
Form 4 Kura Oncology, Inc. For: Nov 18 Filed by: FORD KATHLEEN
Low
Report
Form 4 Kura Oncology, Inc. For: Nov 18 Filed by: FORD KATHLEEN
11/18
04:03 pm
kura
Form 144 Kura Oncology, Inc. Filed by: FORD KATHLEEN
Low
Report
Form 144 Kura Oncology, Inc. Filed by: FORD KATHLEEN
11/14
04:33 pm
kura
Form SC 13G/A Kura Oncology, Inc. Filed by: BIOTECHNOLOGY VALUE FUND L P
Medium
Report
Form SC 13G/A Kura Oncology, Inc. Filed by: BIOTECHNOLOGY VALUE FUND L P
11/14
04:33 pm
kura
Form SC 13G/A Kura Oncology, Inc. Filed by: Paradigm Biocapital Advisors LP
Medium
Report
Form SC 13G/A Kura Oncology, Inc. Filed by: Paradigm Biocapital Advisors LP
11/7
04:18 pm
kura
Form 10-Q Kura Oncology, Inc. For: Sep 30
Low
Report
Form 10-Q Kura Oncology, Inc. For: Sep 30
11/7
04:11 pm
kura
Form 8-K Kura Oncology, Inc. For: Nov 07
Low
Report
Form 8-K Kura Oncology, Inc. For: Nov 07
9/17
04:10 pm
kura
Form 4 Kura Oncology, Inc. For: Sep 13 Filed by: VASCONCELLES MICHAEL
Low
Report
Form 4 Kura Oncology, Inc. For: Sep 13 Filed by: VASCONCELLES MICHAEL
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
4/28
Kura Oncology Inc (NASDAQ: KURA) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $12.00 price target on the stock.
41.3%
5/7 Q1/2019 3/31/2019 EPS -0.370 ZacksConsensus -0.450 ActVsEst 0.080 - Beat 9.6%
5/24 Kura Oncology Inc (NASDAQ: KURA) had its price target raised by analysts at Citigroup Inc from $18.00 to $25.00. They now have a "buy" rating on the stock. 8.3%
4/9 Kura Oncology Inc (NASDAQ: KURA) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $9.25 price target on the stock. 7.9%
3/19 Kura Oncology Inc (NASDAQ: KURA) was downgraded by analysts at BidaskClub from a "sell" rating to a "strong sell" rating. 7.4%
6/18 Form 424B5 Kura Oncology, Inc. 7.1%
9/5 Kura Oncology Inc (NASDAQ: KURA) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $17.00 price target on the stock. 5.9%
10/15 Kura Oncology Expands Board of Directors with Appointment of Diane Parks 4.9%
6/17 Kura Oncology Inc (NASDAQ: KURA) had its "positive" rating re-affirmed by analysts at Wedbush. They now have a $30.00 price target on the stock, up previously from $23.00. 4.6%
2/29 Kura Oncology Inc (NASDAQ: KURA) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $14.00 price target on the stock. 4.1%
5/7 Q1/2019 3/31/2019 EPS -0.370 ZacksConsensus -0.450 ActVsEst 0.080 - Beat 9.6%
5/24 Kura Oncology Inc (NASDAQ: KURA) had its price target raised by analysts at Citigroup Inc from $18.00 to $25.00. They now have a "buy" rating on the stock. 8.3%
4/9 Kura Oncology Inc (NASDAQ: KURA) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $9.25 price target on the stock. 7.9%
3/19 Kura Oncology Inc (NASDAQ: KURA) was downgraded by analysts at BidaskClub from a "sell" rating to a "strong sell" rating. 7.4%
6/18 Form 424B5 Kura Oncology, Inc. 7.1%
9/5 Kura Oncology Inc (NASDAQ: KURA) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $17.00 price target on the stock. 5.9%
10/15 Kura Oncology Expands Board of Directors with Appointment of Diane Parks 4.9%
6/17 Kura Oncology Inc (NASDAQ: KURA) had its "positive" rating re-affirmed by analysts at Wedbush. They now have a $30.00 price target on the stock, up previously from $23.00. 4.6%
2/29 Kura Oncology Inc (NASDAQ: KURA) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $14.00 price target on the stock. 4.1%
TOP News Decliners
3/17
Kura Oncology (KURA) Presents At Cowen and Compnay Health Care Conference - Slideshow [Seeking Alpha]
-14.5%
3/11 Kura Oncology Inc (NASDAQ: KURA) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. -7.8%
6/14 Kura Oncology's stock soars toward record high after trial of lymphoma treatment achieves goal [MarketWatch] -5.0%
8/2 Kura Oncology, Inc. 2019 Q2 - Results - Earnings Call Slides [Seeking Alpha] -4.8%
7/18 Kura Oncology Inc (NASDAQ: KURA) is now covered by analysts at Deutsche Bank AG. They set a "buy" rating and a $28.00 price target on the stock. -4.5%
8/21 Form S-3/A Kura Oncology, Inc. -4.4%
3/4 Form 8-K Kura Oncology, Inc. For: Mar 03 -4.3%
8/21 Kura Oncology Inc (NASDAQ: KURA) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -4.0%
3/17 Form CT ORDER Kura Oncology, Inc. -3.9%
1/23 Kura Oncology Announces Transition of Chief Medical Officer -3.8%
3/11 Kura Oncology Inc (NASDAQ: KURA) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. -7.8%
6/14 Kura Oncology's stock soars toward record high after trial of lymphoma treatment achieves goal [MarketWatch] -5.0%
8/2 Kura Oncology, Inc. 2019 Q2 - Results - Earnings Call Slides [Seeking Alpha] -4.8%
7/18 Kura Oncology Inc (NASDAQ: KURA) is now covered by analysts at Deutsche Bank AG. They set a "buy" rating and a $28.00 price target on the stock. -4.5%
8/21 Form S-3/A Kura Oncology, Inc. -4.4%
3/4 Form 8-K Kura Oncology, Inc. For: Mar 03 -4.3%
8/21 Kura Oncology Inc (NASDAQ: KURA) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -4.0%
3/17 Form CT ORDER Kura Oncology, Inc. -3.9%
1/23 Kura Oncology Announces Transition of Chief Medical Officer -3.8%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: